Can Coherus Oncology (NASDAQ:CHRS) Reach Financial Self-Sufficiency Through Esophageal Cancer Focus?

Sonal Goyal

10 November 2026 06:56 PM AEDT

Can Coherus Oncology (NASDAQ:CHRS) Reach Financial Self-Sufficiency Through Esophageal Cancer Focus?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

LOQTORZI Revenue for the third quarter of 2026 was $14.0 million, a 25% increase.
The company plans to reduce core cash burn by $6 million to $7 million per quarter.
The quarterly LOQTORZI revenue needed to cover core burn is now $25 million to $30 million, down from $30 million to $35 million.
Esophageal cancer has been prioritized as the best-in-disease focus for tagmokitug.

Coherus Oncology, Inc. (NASDAQ:CHRS) reported third-quarter 2026 LOQTORZI revenue of $14.0 million, a 25% increase from the prior-year period. The Redwood City, California-based company said it has prioritized esophageal cancer as the best-in-disease focus for its investigational therapy tagmokitug. The company also outlined a plan to reduce its organization and lower its cost base, with the aim of reaching financial self-sufficiency.

LOQTORZI Sales and Market Focus

Chief Executive Denny Lanfear said the company will remain focused for the next four or five quarters on growing LOQTORZI Market Share in relation to chemotherapy-only treatment and off-label immunotherapy use in nasopharyngeal carcinoma.

LOQTORZI revenue grew 25% from the prior-year quarter to $14.0 million.

Cost Reduction and Breakeven Path

Management expects those changes to reduce core cash burn by $6 million to $7 million per quarter.

That reduction lowers the quarterly LOQTORZI revenue needed to cover core cash burn to $25 million to $30 million, down from $30 million to $35 million previously.

Esophageal Cancer Priority

Lowering the quarterly revenue needed to cover core cash burn from $30 million to $35 million to a range of $25 million to $30 million gives management a lower threshold to reach.

LOQTORZI is an immunotherapy that the company is Marketing in nasopharyngeal carcinoma, where it competes with chemotherapy-only regimens and with off-label use of other immunotherapies.

The reduction in core cash burn of $6 million to $7 million per quarter, which the company linked to the wind-down of a transition services agreement and the completion of a process transfer, lowers the revenue required to reach financial self-sufficiency.

Final Word

LOQTORZI revenue for the third quarter of 2026 was $14.0 million, a 25% increase. The company plans to reduce core cash burn by $6 million to $7 million per quarter.

FAQs

Q: What was LOQTORZI revenue in the third quarter of 2026?

A: LOQTORZI revenue was $14.0 million, a 25% increase from the prior-year quarter.

Q: How much will the company reduce its cash burn?

A: The company expects to reduce core cash burn by $6 million to $7 million per quarter.

Q: What is the new revenue threshold?

A: The quarterly LOQTORZI revenue needed to cover core burn is now $25 million to $30 million, down from $30 million to $35 million.

Q: Which cancer is the company prioritizing for tagmokitug?

A: The company has prioritized esophageal cancer as the best-in-disease focus for tagmokitug.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.